<DOC>
	<DOCNO>NCT00416130</DOCNO>
	<brief_summary>Purpose : - evaluate safety Vorinostat . - evaluate effectiveness Vorinostat treat breast cancer - evaluate study subject 's body react Vorinostat , reaction relate subject 's gene , whether protein change subject blood may use predict subject 's cancer respond Vorinostat We hypothesize Vorinostat , novel class anti-cancer agent , may induce response patient recurrent metastatic breast cancer previously treat anthracyclines taxanes . In addition , hypothesize serum Vorinostat level may correlate clinical response toxicity , Vorinostat may induce unique protein change plasma respond patient , protein may turn use predictive biomarkers treatment response .</brief_summary>
	<brief_title>Clinical Trial SAHA Patients With Breast Cancer</brief_title>
	<detailed_description>Breast cancer sensitive range chemotherapeutics agent , despite initial sensitivity , resistance typically emerge , result disease relapse progression . Exploration novel class agent treatment breast cancer therefore urgent need . Vorinostat SAHA , potent inhibitor histone deacetylase ( HDAC ) activity , represent novel class anti-cancer agent early stage development . Vorinostat active inducing differentiation , cell growth arrest , and/or apoptosis wide variety transform cell culture , show activity breast cancer cell line animal model . Exploratory pharmacokinetic analysis demonstrate oral Vorinostat excellent bioavailability . Oral Vorinostat administer 300 patient enrol complete ongoing clinical study . The maximum tolerated dose ( MTD ) 400 mg q.d . 200 mg b.i.d . continuously , 300 mg b.i.d . x 3 consecutive day per week . Dose-limiting toxicity ( DLT ) non-hematologic ( anorexia , dehydration , diarrhea fatigue ) , resolve quickly drug administration interrupt . This study evaluate safety efficacy Vorinostat breast cancer patient fail anthracyclines taxanes , proven active , add important new class agent treatment armamentarium breast cancer . The study divide 2 phase : phase I determine MTD population , start 400mg q.d . continuously , progressive dose decrement event DLT ; phase 2 determine efficacy Vorinostat MTD 12-37 evaluable patient . Correlative study ( pharmacokinetics , pharmacogenetics , plasma proteomics , tumor histone acetylation , genomics proteomics ) carry identify marker predict treatment response and/or toxicity Vorinostat , achieve future goal tailor therapy .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<criteria>Key Cytologically histologically confirm adenocarcinoma breast recurrent and/or metastatic Must measurable disease define RECIST criterion No 2 prior chemotherapy recurrent and/or metastatic disease exclude neoadjuvant adjuvant chemotherapy Previously receive anthracycline taxanecontaining chemotherapy treatment breast cancer neoadjuvant , adjuvant , metastatic setting Must able swallow capsule Adequate bone marrow reserve liver function Women reproductive age group must agree practice effective contraception entire study period unless documentation infertility exist . Key Prior treatment HDAC inhibitor . Patients receive agent indication , e.g . epilepsy , may enroll trial 30 day washout period . Known CNS involvement tumor Concurrent use oral retinoids vitamin A , single multivitamin tablet daily Acute infection require intravenous antibiotic antifungal agent , know HIV infection , active hepatitis B and/or hepatitis C infection Uncontrolled intercurrent illness Cancer breast cancer exception basal cell carcinoma disease remission â‰¥5 year Pregnant lactating woman</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Phase I/II Clinical Trial</keyword>
	<keyword>Vorinostat</keyword>
	<keyword>SAHA</keyword>
	<keyword>Recurrent Breast Cancer</keyword>
	<keyword>Metastatic Breast Cancer</keyword>
</DOC>